Korn Chotirosniramit

Korn Chotirosniramit

Auto-generated profile, based on publicly available information

Korn Chotirosniramit

Chulalongkorn University 6 Department of Biochemistry, Faculty of Medicine Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
PSPim Sermsaksasithorn
Pim Sermsaksasithorn
TNTanawin Nopsopon
Tanawin Nopsopon
CSChatpol Samuthpongtorn
Chatpol Samuthpongtorn
KCKorn Chotirosniramit
Korn Chotirosniramit
KPKrit Pongpirul
Krit Pongpirul
Introduction Following the discovery of various effects on skin function by modifying endocannabinoid systems, multiple preclinical studies have revealed the promise of cannabis and cannabinoids in the treatment of a variety of skin diseases. However, its clinical efficacy is still debated. Methods and analysis The protocol has been prepared using the Preferred Items for Systematic Review and Meta-analysis Protocols guidelines. A systematic search will be conducted using PubMed, EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials and Web of Science. We will include randomised controlled trials and observational studies investigating alterations to dermatological characteristics following administration of cannabis and cannabinoids for dermatological diseases and disorders. The two reviewers will perform both the title and abstract and full-text screenings. The Cochrane Risk-of-Bias 2 and ROBINS-1 tools will be used to evaluate the risk of bias. If a group of comparable studies for each quantitative outcome can be discovered, we will conduct a random effects meta-analysis. We will investigate heterogeneity using a combination of visual inspection of the forest plot, the Cochran’s Q test and Higgins’ test [I2]. Sensitivity analyses will be performed to assess the statistical robustness of the primary outcome. To evaluate a publication bias, the Egger’s regression asymmetry test and funnel plots will be considered. Ethics and dissemination This study does not require ethical approval because no original data will be collected. The findings will be presented at conferences and published in peer-reviewed journals. PROSPERO registration number CRD42023397189.

30 December 2022 in medRxiv
Verified
Preprint
Open access
PDF file
May Soe ThuMay Soe Thu
May Soe Thu
KCKorn Chotirosniramit
Korn Chotirosniramit
TNTanawin Nopsopon
Tanawin Nopsopon
NHNattiya Hirankarn
Nattiya Hirankarn
KPKrit Pongpirul
Krit Pongpirul
Background: Dysbiosis characterizes breast cancer (BC) through direct or indirect interference in a variety of biological pathways, therefore specific microbial patterns and diversity may be a biomarker for BC diagnosis and prognosis. However, there is still much to determine on the complex interplay of gut microbiome and BC. Objective: To evaluate the microbial alteration in BC patients as compared with control subjects, to explore the gut microbial modification from a range of different BC treatments, and to identify the impact of microbiome patterns on the same treatment-receiving BC patients. Methods: A literature search was conducted using electronic databases such as PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library to April 2021. The search was limited to adult BC women and the English language. A prespecified subgroup analysis in BC patients was performed. The results were synthesized quantitatively and qualitatively using random-effects meta-analysis. Results: A total of 33 studies were included in the review, accounting for 20 case-control, 8 cohort, and 5 non-randomized intervention studies. In the meta-analysis, the bacterial DNA load is reduced in the tumor compared with paired normal breast and healthy breast tissue, and interestingly, there is an inverse correlation of the bacterial load in different breast tumor stages. From the intervention studies, it revealed 41 species related to breast tumors with a predominance of Gemella haemolysans and Streptococcus mitis , and after chemotherapy, the number of species per patient was elevated by a mean of 2.6 (SD = 4.7, p = 0.052). Also, the tumor tissue showed a significant reduction of transcripts of microbial sensors such as TLR2, TLR5, and TLR9, cytoplasmic microbial sensors like NOD1 and NOD2, and the levels of BPI, MPO, and PRTN3. It found that the post-menopausal group has higher leucine-and valine-arylamidase, β-glucuronidase, and esterase-lipase activities in contrast to pre-menopausal and healthy groups. Conclusions: This systematic review elucidates the complex network of the microbiome, BC, and the therapeutic options, expecting to provide a link for stronger research studies and toward personalized medicine to improve their quality of life. Funding: None. Registration ID: PROSPERO 2021 CRD42021288186

9 June 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
NPNussara Pakvisal
Nussara Pakvisal
PWPiriya Wongkongkathep
Piriya Wongkongkathep
WBWorawan Bunrasmee
Worawan Bunrasmee
PSPimpayao Sodsai
Pimpayao Sodsai
JSJirattha Siriluksana
Jirattha Siriluksana
TPTrairak Pisitkun
Trairak Pisitkun
Purpose: To evaluate the safety and immunogenicity of intramuscularly delivered personalized neoantigen synthetic long peptide (SLP) vaccines in patients with advanced solid tumors. Patients and Methods: In this phase I trial, 12 patients with advanced melanoma (n = 9) or renal cell carcinoma (n = 3) who lacked access to further reimbursed standard therapies at enrollment received intramuscular neoantigen SLP vaccines with Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC). Each vaccine contained about 20 predicted neoantigen peptides. Adverse events were monitored throughout vaccination and follow-up. Immune profiling was performed at baseline and predefined postvaccination time points. Results: Intramuscular neoantigen vaccination was well tolerated, with only grade 1 to 2 local pain or fever and no immune-mediated toxicities. All participants developed de novo T-cell responses, which were detectable as early as 1 week after vaccination in most patients. On average, 53% of peptides per patient were immunogenic, inducing both CD8+ and CD4+ neoantigen-specific responses. Patients previously treated with immune checkpoint inhibitors (ICI) had higher baseline immunity but achieved comparable postvaccination responses to ICI-naïve patients. IFNγ-dominant CD8+ and TNFα-dominant CD4+ responses were observed, along with increased effector memory differentiation. Two patients with higher CD8+ terminal effector memory RA (TEMRA) proportions were the longest survivors. Tumor biopsies revealed enhanced CD8+ infiltration, and epitope spreading occurred in two evaluable cases. An analysis of 239 peptides showed greater immunogenicity for dual MHC I/II–binding, cysteine-containing, in-frame insertions or deletions–derived or low variant allele frequency–derived mutations, whereas proline substitutions reduced responses. Conclusions: Intramuscular neoantigen SLP vaccination with poly-ICLC is safe and induces rapid, mutation-specific T-cell immunity with robust CD8+ effector responses. These findings support intramuscular administration as a promising strategy for peptide-based cancer vaccines.

3 August 2026
Verified
Other
Open access
NPNussara Pakvisal
Nussara Pakvisal
PWPiriya Wongkongkathep
Piriya Wongkongkathep
WBWorawan Bunrasmee
Worawan Bunrasmee
PSPimpayao Sodsai
Pimpayao Sodsai
JSJirattha Siriluksana
Jirattha Siriluksana
TPTrairak Pisitkun
Trairak Pisitkun
Supplementary Data 3 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma

3 August 2026
Verified
Other
Open access
NPNussara Pakvisal
Nussara Pakvisal
PWPiriya Wongkongkathep
Piriya Wongkongkathep
WBWorawan Bunrasmee
Worawan Bunrasmee
PSPimpayao Sodsai
Pimpayao Sodsai
JSJirattha Siriluksana
Jirattha Siriluksana
TPTrairak Pisitkun
Trairak Pisitkun
Supplementary Data 2 from The Phase Ib IMPACT Trial of Intramuscular Personalized Neoantigen Synthetic Long Peptide Vaccines in Patients with Advanced Melanoma and Renal Cell Carcinoma